Ulcerative Colitis: Pharmacotherapy and Treatment Selection

Establish Diagnosis and Stratify Severity

Ulcerative colitis (UC) causes continuous mucosal inflammation beginning in the rectum, with variable proximal colonic extension. Common symptoms are rectal bleeding, urgency, tenesmus, frequent stools, abdominal cramping, and fatigue. Confirm diagnosis and extent with colonoscopy and biopsy; assess hemoglobin, inflammatory markers including C-reactive protein and fecal calprotectin, and infections as appropriate. Disease extent is clinically consequential: proctitis, left-sided colitis, and extensive disease have different topical versus oral drug-delivery needs (Bhat, 2026; Rubin et al., 2025).

Complication risk is not synonymous with current symptom intensity. Frequent relapse, deep ulcers, extensive inflammation, elevated biomarkers, steroid dependence, or hospitalization can justify earlier advanced treatment. Exclude infectious colitis, particularly C. difficile during an apparent flare, and recognize severe bleeding, fever, tachycardia, systemic toxicity, and marked distension as potential acute severe colitis or toxic megacolon (Bhat, 2026; Rubin et al., 2025).

Mild-to-Moderate Disease: Direct 5-ASA to Affected Colon

Clinical phenotype	Preferred induction strategy	Reasoning / next decision
Isolated ulcerative proctitis	Mesalamine suppository 1 g rectally daily.	Local drug concentration at the rectum is more relevant than increasing oral therapy alone.
Left-sided colitis	Mesalamine enema at least 1 g/day plus oral 5-ASA at least 2 g/day.	Combination oral and rectal exposure treats both distal and more proximal inflammation.
Extensive colitis	Oral mesalamine at least 2 g/day; consider rectal therapy for persistent distal symptoms.	Account for the distribution and formulation-dependent release of mesalamine.
Inadequate response to optimized 5-ASA	Budesonide MMX 9 mg orally once daily for induction, or systemic corticosteroid according to severity.	Check adherence, dose, infection, and inflammatory activity rather than switching endlessly among similar 5-ASA brands.

The 2025 ACG guideline supports the above location-directed dosing strategies. Once induction succeeds, mild proctitis can remain on rectal 5-ASA 1 g daily; for left-sided or extensive disease, oral 5-ASA at least 1.5 g/day is an established maintenance option. Steroids, including budesonide MMX, are not maintenance drugs (Rubin et al., 2025).

Drug-Class Pharmacology and Safety

Class / examples	Place in therapy	Major safety and monitoring considerations
Aminosalicylates: mesalamine, sulfasalazine	First-line in appropriate mild-to-moderate UC and maintenance after response.	Monitor renal function; assess intolerance, pancreatitis, hypersensitivity, and adherence. Sulfasalazine requires folate considerations. Product-specific mesalamine renal and hypersensitivity warnings are detailed in the original FDA labeling (Zydus Pharmaceuticals USA Inc., 2026).
Glucocorticoids: budesonide MMX, prednisone, IV methylprednisolone	Induction or rescue bridge, never long-term disease control.	Use an indication-appropriate steroid with an explicit taper/exit strategy; screen for steroid-related complications according to dose, duration, and patient risk.
Thiopurines: azathioprine, mercaptopurine	Select maintenance contexts, not rapid induction.	TPMT and NUDT15 assessment; CBC and liver monitoring; infection, pancreatitis, lymphoma and skin cancer considerations (Oceanside Pharmaceuticals, 2025).
Advanced therapies: anti-TNF, integrin, IL-12/23 or IL-23 antagonists, JAK inhibitors, S1P modulators	Moderate-to-severe disease and risk-based escalation with GI specialist.	Perform infection screening, vaccination review, and baseline assessment required by the selected drug; individual cardiovascular, malignancy, laboratory, and pregnancy warnings differ by product.

Moderate-to-Severe UC: Avoid Reflexive Slow Step-Up

The AGA living guideline supports early advanced therapy, rather than requiring multiple ineffective conventional steps in appropriate moderate-to-severe UC. Infliximab, vedolizumab, ustekinumab, risankizumab, guselkumab, upadacitinib, and several other agents are options, but comparative effectiveness depends on prior biologic exposure, treatment objective, patient characteristics, and safety. The AGA living recommendations were reviewed in March 2026 without change. Thiopurines and methotrexate are not appropriate monotherapy for inducing active moderate-to-severe UC; methotrexate is not recommended as UC monotherapy for maintenance (Singh et al., 2024).

Agent selection cannot be reduced to a single universal preferred biologic. Consider prior anti-TNF exposure, primary nonresponse versus secondary loss of response, extraintestinal manifestations, infection history, heart failure, thromboembolic and cardiovascular risk, childbearing plans, and preference for oral versus infusion or injection treatment. Before prescribing an advanced agent, verify its current indication, exact induction and maintenance regimen, age restrictions, contraindications, and FDA label rather than borrowing a dose from another IBD indication (Bhat, 2026; Singh et al., 2024).

Acute Severe UC Is a Hospital-Level Syndrome

Multiple bloody stools with systemic toxicity, anemia, substantial inflammatory abnormalities, or distension require urgent evaluation. In hospitalized acute severe UC, management includes fluids, electrolyte correction, infection testing including C. difficile, thromboprophylaxis when appropriate, and IV corticosteroids. Poor early response requires prompt specialist coordination for rescue therapy and surgical evaluation; oral mesalamine or symptomatic antidiarrheals must not replace the inpatient acute-severe-UC treatment and rescue pathway (Bhat, 2026; Rubin et al., 2025).

Advanced-Therapy Dose Discrimination: Adult UC

The following representative FDA-label regimens are indication-specific and do not rank treatments by comparative efficacy. Their purpose is to prevent substitution of psoriasis, Crohn, rheumatoid arthritis, or other formulations/doses for an ulcerative colitis prescription. Current label restrictions and exact product instructions must govern dispensing (AbbVie Inc., 2026a, 2026b; Celgene Corporation, 2026; Eli Lilly and Company, 2026; Janssen Biotech, Inc., 2025, 2026a, 2026b, 2026c; Pfizer Laboratories Div Pfizer Inc, 2025; Takeda Pharmaceuticals America, Inc., 2026).

Drug / mechanism	Labeled adult UC induction	Labeled adult UC maintenance
Infliximab (anti-TNF)	5 mg/kg IV at weeks 0, 2, and 6.	5 mg/kg IV every 8 weeks (Remicade reference product).
Vedolizumab (alpha-4-beta-7 integrin)	300 mg IV at weeks 0 and 2.	From week 6: 300 mg IV every 8 weeks OR 108 mg SC every 2 weeks; stop if no benefit by week 14.
Ustekinumab (IL-12/23)	Single IV weight-based induction: <=55 kg, 260 mg; >55–85 kg, 390 mg; >85 kg, 520 mg.	90 mg SC at week 8 after IV induction, then every 8 weeks.
Risankizumab (IL-23)	1,200 mg IV at weeks 0, 4, 8; infuse over >=2 hours.	180 or 360 mg SC at week 12 and every 8 weeks thereafter; lowest effective.
Mirikizumab (IL-23)	300 mg IV at weeks 0, 4, 8.	200 mg SC at week 12 and every 4 weeks thereafter.
Guselkumab (IL-23)	200 mg IV OR 400 mg SC at weeks 0, 4, 8.	100 mg SC at week 16 then every 8 weeks OR 200 mg SC at week 12 then every 4 weeks.
Upadacitinib (JAK1)	45 mg orally daily for 8 weeks in eligible adults.	15 mg daily; 30 mg may be considered for refractory, severe, or extensive disease. Drug interactions/organ dysfunction may change dosing.
Ozanimod (S1P modulator)	Days 1–4: 0.23 mg daily; days 5–7: 0.46 mg daily.	Day 8 onward: 0.92 mg orally daily; hepatic modifications may apply.
Etrasimod (S1P modulator)	2 mg orally once daily; no 7-day titration regimen.	Continue 2 mg once daily; pretreatment ECG is required.

Prescribing-label source note: Consult the indication-specific U.S. product labels cited in the references (AbbVie Inc., 2026a, 2026b; Celgene Corporation, 2026; Eli Lilly and Company, 2026; Janssen Biotech, Inc., 2025, 2026a, 2026b, 2026c; Pfizer Laboratories Div Pfizer Inc, 2025; Takeda Pharmaceuticals America, Inc., 2026); verify the current formulation, dose, warnings and population before use.

The 2026 Rinvoq label specifies that use for UC follows inadequate response or intolerance to a TNF blocker; when TNF blockers are clinically inadvisable, patients must have tried at least one approved systemic therapy. The AGA efficacy ranking does not override this U.S. prescribing restriction (AbbVie Inc., 2026a; Singh et al., 2024).

Advanced-Drug Selection Requires Drug-Specific Pretreatment Checks

Treatment group	Specific assessment / contraindication discrimination
Anti-TNF (e.g., infliximab, golimumab)	Test for latent TB and HBV, assess active infections and serious hypersensitivity; consider demyelinating disease and moderate/severe heart failure. Avoid unsupported interchanging of SC and IV products.
IL-23 agents (risankizumab, mirikizumab, guselkumab)	Assess TB, active infection and vaccination status. Obtain baseline liver enzymes and bilirubin for risankizumab/mirikizumab; comply with product-specific liver monitoring, especially during induction.
JAK1 inhibitor (upadacitinib)	Evaluate infection/TB/HBV risk, CBC, hepatic status, pregnancy potential, lipid assessment, cardiovascular/VTE/malignancy risks and concomitant CYP3A4 drugs. Serious infection, mortality, malignancy, MACE and thrombosis boxed warnings.
S1P modulators (ozanimod, etrasimod)	ECG, CBC/lymphocytes, liver tests, VZV immunity, ophthalmic/skin considerations, drug interactions and cardiac-history assessment. Etrasimod is contraindicated with recent MI/stroke and certain conduction blocks; ozanimod requires titration.
Vedolizumab	Evaluate infection risk, immunizations and consider TB screening. IV induction is not equivalent to starting a 108-mg SC pen de novo.

Pediatric Label Distinctions

Current subcutaneous Simponi labeling includes pediatric moderate-to-severe UC at weights of at least 15 kg, using weight-specific induction and maintenance rather than the adult rheumatologic regimen. The September 2026 Stelara label includes pediatric UC in children aged 2 years or older weighing at least 10 kg, with weight-based IV induction followed by weight-specific subcutaneous maintenance. Product, age, weight, route and indication must each be confirmed; adult dosing cannot be assumed for children (Janssen Biotech, Inc., 2026a, 2026b).

Clinical application: A biologic-naïve adult with severe extensive UC and elevated fecal calprotectin may be a candidate for early advanced therapy rather than repeated prednisone tapers. Once an agent is selected, reconcile the actual UC induction dose, route, week-by-week schedule, infection screening, and a measurable steroid-free treatment target before the first administration (Singh et al., 2024).

Monitoring, Stewardship, and Failure

• Document bleeding, urgency, stool frequency and function, with fecal calprotectin/CRP and endoscopic targets when appropriate; distinguish clinical response from objective healing.
• Review route and adherence for rectal and oral 5-ASA before declaring treatment failure. Measure renal function with ongoing mesalamine exposure.
• Document a steroid-free maintenance plan at the start of a steroid course; repeated courses or dependence should prompt escalation.
• Screen hepatitis B and tuberculosis as relevant before biologics; update immunizations and obtain drug-specific baseline labs before therapy.
• Reassess persistent symptoms for active inflammation, C. difficile, alternate diagnosis, and treatment complications rather than simply layering symptomatic medication.

Key clinical distinction: Mesalamine can be a foundation of uncomplicated UC management, but it is not a substitute for timely advanced therapy when prognostic or inflammatory severity warrants escalation (Rubin et al., 2025; Singh et al., 2024).

Extent and Severity Determine Induction, Not Drug Availability Alone

For uncomplicated mild ulcerative proctitis, rectal mesalamine delivers 5-ASA to the affected distal mucosa and is generally preferred to oral-only therapy. Left-sided disease often warrants combined oral and rectal mesalamine rather than treating extent-independent symptoms with one oral tablet. Extensive mild-to-moderate disease typically calls for optimized oral mesalamine; budesonide MMX or a short systemic corticosteroid course may be appropriate for selected nonresponders. Corticosteroids induce remission but must not be used for maintenance (Rubin et al., 2025).

High inflammatory burden, repeated steroid exposure, hospitalization, severe endoscopic lesions and high-risk features favor timely advanced therapy. For moderate-to-severe UC, the AGA living guideline supports early advanced therapy rather than mandatory prolonged 5-ASA step-up. Compare mechanism, expected effectiveness after prior biologic exposure, infection/thrombosis/cardiovascular risk, pregnancy planning, route preference, access and monitoring; comparative drug rankings are population-level data, not a direct substitute for contraindication review (Singh et al., 2024).

Induction, Maintenance, and Failure Are Three Separate Decisions

Adequate induction is measured by improvement in bleeding, stool frequency, urgency and CRP/fecal calprotectin, followed by objective assessment of mucosal inflammation. A patient may report symptom relief despite persistent endoscopic disease. Define steroid-free remission and a maintenance plan at the outset. Avoid treating repeated steroid courses as successful maintenance, and do not stop effective maintenance solely because symptoms resolved (Rubin et al., 2025; Singh et al., 2024).

For ongoing symptoms on an advanced agent, assess adherence, timing of induction doses, infection including C. difficile, objective inflammation, immunogenicity and medication exposure before labeling primary nonresponse or secondary loss of response. Therapeutic drug monitoring has particular utility for anti-TNF agents when loss of response is suspected; appropriate dose optimization or a mechanism switch depends on antibody and trough context. Mechanism switching without first verifying active inflammation can expose patients with functional symptoms to avoidable immunosuppression (Bhat, 2026).

Acute Severe UC: Day-Three Decision and Surgical Safety

Acute severe UC requires inpatient assessment, exclusion of C. difficile, evaluation for toxic megacolon, pharmacologic VTE prophylaxis where indicated, early flexible sigmoidoscopy with biopsies including CMV assessment when appropriate, and intravenous corticosteroids. The ACG recommends reassessing by day 3: inadequate response should prompt rescue consideration with infliximab or cyclosporine and timely colorectal surgical input. Perforation, toxic megacolon, major hemorrhage or failure of rescue changes disposition toward surgery; bowel rest and broad-spectrum antibiotics are not routine substitutes for evidence-based care (Rubin et al., 2025).

Decision pathway: UC presentation

UC presentation	Induction logic	Maintenance or escalation endpoint
Mild proctitis	Rectal mesalamine targeted to involved segment; evaluate adherence and local tolerability.	Maintain effective 5-ASA; reassess bleeding and objective activity where needed.
Mild left-sided colitis	Combine oral and rectal 5-ASA; optimize before class switch.	Review steroid-free response and adherence; persistent bleeding prompts re-evaluation.
Moderate–severe or steroid-dependent	Early advanced therapy selected for risks, prior exposures and preferences.	Clinical/biomarker response and objective remission; maintain effective advanced agent.
Hospitalized acute severe UC	IV corticosteroid with infection/complication evaluation and VTE prevention.	Assess day-3 trajectory; infliximab/cyclosporine rescue or surgical pathway when needed.

Applied Clinical Case and Prescribing Rationale

Scenario: A 29-year-old with left-sided UC has four bloody stools daily despite taking oral mesalamine inconsistently. A second patient is hospitalized with ten bloody stools daily, tachycardia and CRP elevation after failing outpatient steroids. Should both receive the same escalation?

Reasoned response: No. The first patient needs assessment of adherence, objective inflammation and addition/optimization of rectal mesalamine for left-sided distribution before declaring class failure. The second needs an acute severe UC pathway, infection testing, VTE prevention, IV steroids, early endoscopic/surgical assessment and day-3 rescue decision; simply increasing the outpatient mesalamine dose would be unsafe (Rubin et al., 2025).

Pregnancy and Reproductive Planning

Before conception, pursue sustained control of intestinal inflammation and coordinate gastroenterology and obstetric care. The 2025 global IBD pregnancy consensus recommends continuing established 5-ASA treatment during pregnancy and discontinuing methotrexate before conception; do not stop effective maintenance therapy reflexively because of pregnancy. Biologic and small-molecule decisions require agent-specific safety review and coordination, particularly when switching treatment during pregnancy (Mahadevan et al., 2025).

High-Yield Distinctions

Related YourDNP Resources

Pharmacology learning hub | Crohn Disease | Acute Diarrhea

---

---

References

AbbVie Inc. (2026a, June 30). Rinvoq (upadacitinib) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095

AbbVie Inc. (2026b, June 15). Skyrizi (risankizumab-rzaa) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858

Bhat, S. (2026). Inflammatory bowel disease. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 20). McGraw Hill.

Celgene Corporation. (2026, April 16). Zeposia (ozanimod) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93ce2fab-edfb-4804-8074-963071de51e4

Eli Lilly and Company. (2026, June 16). Omvoh (mirikizumab-mrkz) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=472cbe04-263e-433d-9a0f-58c1b50b715a

Janssen Biotech, Inc. (2025, June 3). Remicade (infliximab) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257

Janssen Biotech, Inc. (2026a, September 17). Simponi (golimumab) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f86cb4a7-c358-4136-ae57-b32bda9bba00

Janssen Biotech, Inc. (2026b, September 8). Stelara (ustekinumab) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c77a9664-e3bb-4023-b400-127aa53bca2b

Janssen Biotech, Inc. (2026c, June 4). Tremfya (guselkumab) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56

Mahadevan, U., Seow, C. H., Barnes, E. L., Chaparro, M., Flanagan, E., Friedman, S., Julsgaard, M., Kane, S., Ng, S., Torres, J., Watermeyer, G., Yamamoto-Furusho, J., Robinson, C., Fisher, S., Anderson, P., Gearry, R., Duricova, D., Dubinsky, M., Long, M. D., & Global Consensus Group for Pregnancy and IBD. (2025). Global consensus statement on the management of pregnancy in inflammatory bowel disease. Inflammatory Bowel Diseases, 31(10), 2615–2664. https://doi.org/10.1093/ibd/izaf171

Oceanside Pharmaceuticals. (2025, September 22). Azathioprine tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d72ede2c-1a9b-4717-80a7-b76a6a499936

Pfizer Laboratories Div Pfizer Inc. (2025, August 18). Velsipity (etrasimod) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=65171e4a-d136-4abc-b08c-c40c1b486ff6

Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Barnes, E. L., & Long, M. D. (2025). ACG clinical guideline update: Ulcerative colitis in adults. American Journal of Gastroenterology, 120(6), 1187–1224. https://doi.org/10.14309/ajg.0000000000003463

Singh, S., Loftus, E. V., Jr., Limketkai, B. N., Haydek, J. P., Agrawal, M., Scott, F. I., & Ananthakrishnan, A. N. (2024). AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology, 167(7), 1307–1343. https://doi.org/10.1053/j.gastro.2024.10.001

Takeda Pharmaceuticals America, Inc. (2026, April 29). Entyvio (vedolizumab) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c

Zydus Pharmaceuticals USA Inc. (2026, July 14). Mesalamine delayed-release tablets [Prescribing information]. DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad8c7930-92e2-4372-a874-da22b9ae333e